Interleukin-2 and Interleukin-12 in Treating Patients With Refractory or Advanced Solid Tumors

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Breast Cancer
			Kidney Cancer
			Lung Cancer
			Ovarian Cancer
			Sarcoma
2		Additional conditions recognized in this trial
			Breast Neoplasms
			Carcinoma, Renal Cell
			Kidney Neoplasms
			Lung Neoplasms
			Ovarian Neoplasms
3		More general conditions related to this trial
			Adenocarcinoma
			Adnexal Diseases
			Breast Diseases
			Carcinoma
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Genital Diseases, Female
			Genital Neoplasms, Female
			Gonadal Disorders
			Kidney Diseases
			Lung Diseases
			Neoplasms
			Neoplasms by Histologic Type
			Neoplasms by Site
			Neoplasms, Connective and Soft Tissue
			Neoplasms, Glandular and Epithelial
			Ovarian Diseases
			Respiratory Tract Diseases
			Respiratory Tract Neoplasms
			Skin Diseases
			Thoracic Neoplasms
			Urogenital Neoplasms
			Urologic Diseases
			Urologic Neoplasms
4		Interventions listed in this trial
			aldesleukin
			recombinant interleukin-12
5		Additional drug interventions recognized in this trial
			Interleukin-12
6		More general drug interventions related to this trial
			Adjuvants, Immunologic
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Anti-HIV Agents
			Anti-Infective Agents
			Anti-Retroviral Agents
			Antineoplastic Agents
			Antiviral Agents
			Growth Inhibitors
			Growth Substances
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			National Cancer Institute (NCI)